Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).

Publication

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).

Journal Paper/Review - Jan 26, 2023

Achtnichts Lutz, Zecca Chiara, Findling Oliver, Kamm Christian Philipp, Müller Stefanie, Kuhle Jens, Lutterotti Andreas, Gobbi Claudio, Viviani Camille, Villiger-Borter Emanuela, Nedeltchev Krassen

Citation

Achtnichts L, Zecca C, Findling O, Kamm C, Müller S, Kuhle J, Lutterotti A, Gobbi C, Viviani C, Villiger-Borter E, Nedeltchev K. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). BMJ Neurol Open 2023; 5:e000304.

Type

Journal Paper/Review (English)

Journal

BMJ Neurol Open 2023; 5

Publication Date

Jan 26, 2023

Issn Electronic

2632-6140

Pages

e000304

Brief description/objective

In patients with multiple sclerosis (MS), relapses and disability progression have been associated with decreased health-related quality of life (HRQoL).